Long-term efficacy of vasodilating β-blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry

• Main Authors: Jaehoon Chung, Jung-Kyu Han, Han-Mo Yang, Kyung-Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Myung Ho Jeong, Hyo-Soo Kim, on behalf of investigators for Korea Acute Myocardial Infarction Registry (KAMIR)
• Format: Article
• Language: English
• Published: The Korean Association of Internal Medicine 2021-03-01
• Series: The Korean Journal of Internal Medicine
• Subjects: beta-blocker; myocardial infarction; coronary artery disease; percutaneous coronary intervention
• Online Access: http://www.kjim.org/upload/pdf/kjim-2020-135.pdf

Background/Aims Long-term benefit of vasodilating β-blockers is unknown. This study aimed to investigate the long-term benefit of vasodilating β-blockers over conventional β-blockers in patients with acute myocardial infarction (AMI). Methods Using nationwide prospective multicenter Korean Acute Myocardial Infarction Registry data, we analyzed 3-year clinical outcomes of 7,269 patients with AMI who received percutaneous coronary intervention (PCI) and β-blocker therapy. Patients were classified according to treatment strategy (vasodilating β-blockers vs. conventional β-blockers). The primary endpoint was a composite of cardiac death, myocardial infarction (MI), and hospitalization for heart failure (HF) at 3 years. Secondary outcomes were each component of the primary outcome. Propensity score matching was performed to adjust for differences of baseline characteristics. Results In 3,079 pairs (6,158 patients) of propensity score-matched patients, the primary outcome occurred significantly less in the vasodilating β-blockers group compared with the conventional β-blockers group (7.6% vs. 9.8%, p = 0.003). Among the secondary outcomes, cardiac death occurred significantly less in the vasodilating β-blockers group than in the conventional group (3.5% vs. 4.8%, p = 0.015). The incidence rates of MI (2.4% vs. 3.0%, p = 0.160) or hospitalization for HF (2.6% vs. 3.2%, p = 0.192) were not significantly different between the two groups. Conclusions Vasodilating β-blocker therapy was associated with better clinical outcomes compared with conventional β-blocker therapy in AMI patients undergoing PCI during 3 years follow-up. Vasodilating β-blockers could be recommended preferentially for these patients.